Goldman Sachs
ACTU

Goldman Sachs’s Actuate Therapeutics ACTU Stock Holding History

Goldman Sachs’s Portfolio ACTU Stock Details ACTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$54.3K Buy
35,498
+23,090
+186% +$53.5K ﹤0.01% 6403
2026
Q1 		$34K Buy
+12,408
New +$51.4K ﹤0.01% 6328
2025
Q2 		– Sell
-22,358
Closed -$151K – 6520
2025
Q1 		$151K Buy
22,358
+11,105
+99% +$89.2K ﹤0.01% 5700
2024
Q4 		$89.6K Buy
+11,253
New +$91.8K ﹤0.01% 5782

Other funds holding ACTU

BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
VC
Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.87B AUM 24.49% 1-Year Est. Return
PVM
Palogic Value Management Dallas, Texas $304M AUM 15.15% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ADEF
ABS Direct Equity Fund Stamford, Connecticut $159M AUM 34.17% 1-Year Est. Return

Goldman Sachs's ACTU Position: Q2 2026 in Review

Goldman Sachs increased its Actuate Therapeutics (ACTU) stake by 186% in Q2 2026, buying an estimated $53.5K and bringing the position to 35,498 shares worth $54.3K. The position accounts for ﹤0.01% of the portfolio, ranked #6403.

Goldman Sachs first reported a position in ACTU in Q4 2024 and has held it in 4 quarters since. The position peaked at $151K in Q1 2025. 64 funds tracked by Wall St. Rank hold ACTU as of Q2 2026.

  • Goldman Sachs held 35,498 shares of Actuate Therapeutics worth $54.3K as of Q2 2026.
  • Goldman Sachs bought 23,090 Actuate Therapeutics shares in Q2 2026, an estimated $53.5K.
  • Actuate Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #6403 holding.
  • Goldman Sachs first reported a position in Actuate Therapeutics in Q4 2024 and has held it in 4 quarters since.
  • Goldman Sachs's Actuate Therapeutics position peaked at $151K in Q1 2025.
  • 64 funds tracked by Wall St. Rank held Actuate Therapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.